
Hematology Oncology Fellowship in The “Golden Era” of Cancer Research
Matthew Karr, DO, highlights advances in the CLL paradigm, current goals in researching CNS lymphoma, and other future directions in hematology/oncology.
In a special edition of Oncology On the Go, Matthew Karr, DO, joined CancerNetwork® in the studio to discuss his work and ambitions as they relate to the hematology/oncology field. In addition to outlining the mentorship and initial efforts that defined his time thus far as a fellow, Karr described how he aims to contribute to the cancer care continuum across different research initiatives in chronic lymphocytic leukemia (CLL), central nervous system (CNS) lymphomas, and other malignancies.
Karr, a hematology/oncology fellow at RWJBarnabas Health, detailed how his first year of fellowship involved inpatient-heavy responsibilities such as various consults and transplant services, which eventually evolved to outpatient subspecialty clinics and research efforts in later years. His work, he said, is taking place in the “golden era of cancer research” due to the rapid advancement of novel drug approvals and breakthroughs, touching upon the significance of recent evolutions such as KRAS-targeted therapies in pancreatic cancer.
Reflecting on a manuscript detailing the history of targeted therapy developments for patients with CLL that he published in 2023 with Lindsey E. Roeker, MD, a hematologist/oncologist at Mayo Clinic in Rochester, Minnesota, Karr noted how the field has evolved since that initial publication and described what other needs clinicians must address in the future. Although CLL outcomes have improved significantly with the help of novel targeted regimens, he said that current goals include exploring novel triplet combinations and offering time-limited vs continuous therapy based on individual patient preferences.
In terms of future research initiatives, Karr expressed his interest in investigational modalities like in vivo CAR T cells and novel targets such as p53 reactivation. Other notable goals, he said, include assessing bispecific antibodies in CNS lymphoma and researching how oncologists grade artificial intelligence (AI)–generated responses to leukemia-related questions, which may help further clarify the technology’s role in medicine.
“If you’re passionate about it, pursue it…There are fields of medicine that are less emotionally draining, but I would say that it’s also one of the most rewarding,” Karr said when offering advice to any medical students or residents considering the field of hematology/oncology. “One of the most things is working with like-minded people who are on the forefront of a really exciting scientific field. I think there’s a lot of appeal to it, so that’s why I say if you like it, pursue it. We want more people who are passionate about what they do.”
Reference
Karr M, Roeker L. A history of targeted therapy development and progress in novel-novel combinations for chronic lymphocytic leukemia (CLL). Cancers (Basel). 2023;15(4):1018. doi:10.3390/cancers15041018
Related to this article








